CMT 167 Cell Line

Exclusive Tool

A syngeneic murine lung cancer model used to study immune checkpoint blockade, metastatic disease, and tumour microenvironment interactions. Available only through CancerTools. Save 30% on this cell line this summer. Use code SUM26CELL at checkout.

Contributors

Inventor Institute
Peter Riddle Cancer Research UK, London Research Institute: Lincoln's Inn Fields
SKU: 151448
Product description: CMT 167 is a highly metastatic murine alveogenic lung carcinoma cell line, derived from the parental CMT 64 line. Developed in 1984 at the Cancer Research UK London Research Institute (Lincoln’s Inn Fields), CMT 167 was established through subcloning and in vivo selection for enhanced metastatic potential from pooled lung metastases of CMT 64. Compared to CMT 64, CMT 167 exhibits a markedly higher propensity for metastasis and is a useful tool to investigate the mechanisms and origins of metastatic progression in lung cancer.
Alternate name: CMT167; CMT-167
Gender: Female
Conditional: Yes
Production details: CMT 167 is a subclone of the CMT 64 alveogenic lung carcinoma cell line, originally derived from a primary tumour in a C57BL/1CRF mouse. To generate CMT 167, adult female C57B/T mice (aged 4–6 months) were subcutaneously injected in the lower right flank using a Bashford needle. The injected material consisted of pooled tumour fragments taken from various non-necrotic regions of CMT 64-derived tumours. Following tumour development, cells were harvested from resulting lung metastases. Epithelial outgrowths from these metastatic sites were cultured and selectively expanded based on their high metastatic potential. Through this process of subcloning and in vivo screening, the CMT 167 cell line was established as a more aggressively metastatic variant of CMT 64.
Cellosaurus ID: CVCL_2405
Disease: Cancer
Cat. #: 151448
Provenance and Ownership: The CMT 167 Cell Line is owned by Cancer Research UK. CancerTools supplies the CMT 167 Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing CMT 167 Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements.
Tool sub type: Primary
Unit size: 1×10^6 cells / vial
Cancer types: Lung cancer
Organism: Mouse
Tissue: Lung
Gender: Female
Model: Cancer cell line
Morphology: Epithelial cell line, with closely packed sheets at confluence.
Growth properties: Adherent
Cancer Types In Detail: Lung carcinoma
Primary citation: Layton and Franks. 1984. Br J Cancer. 49(4):415-21. PMID: 6324836.
Format: Frozen
Shipping conditions: Dry ice
Growth medium: DMEM with 2mM Glutamine and 10% FCS
Subculture routine: Split sub-confluent cultures (70-80%) 1:4 to 1:10 seeding at approximately 3 x 10^4 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Saturation density 1.2 x 10^5 cells/cm². Please also see detailed protocol within the Product Datasheet in the Documentation section below.
References:

Bullock et al. 2019. Life Sci Alliance. 27:2(3): e201900328. PMID: 31133614

Tippimanchai et al. 2018. Oncoimmunology. 7(6):e1438105. PMID: 29872579

Seshadri et al. 2018. Front Pharmacol. 9:759. PMID: 30061830

Li et al. 2017. Cancer Immunol Res. 9: 767-777. PMID: 28819064

Pelaz et al. 2017. ACS Nano. 11(3):2313-2381. PMID: 28290206

Evans et al. 2009. Cancer Res. 69(5):1733-8. PMID: 19208832

Ismail et al. 2000. Cancer Res. 60(5):1173-6. PMID: 10728668

Franks and Layton. 1984. Br J Cancer. 49(4):423-9. PMID: 6324837

Layton and Franks. 1984. Br J Cancer. 49(4):415-21. PMID: 6324836

Franks et al. 1976. Cancer Res. 36(3):1049-55. PMID: 1253168

Images

View Gallery
CMT 167 Cell Line 2. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC)

Citations And Reviews

Related Tools for Cell lines

Cat. # Tool Name
151447 CMT 64 Cell Line Key Info View Tool
153332 CMT 170 Cell Line Key Info View Tool
152751 CMT 64/61 Cell Line Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.